CJC-1295 Stack: Common Combinations, Dosages, and Safety

A CJC-1295 stack is the practice of combining CJC-1295, a growth hormone-releasing hormone (GHRH) analog, with a second peptide such as ipamorelin, tesamorelin, sermorelin, or AOD-9604. The research rationale is to influence growth hormone (GH) and IGF-1 signaling through more than one receptor pathway instead of one. No CJC-1295 stack is FDA-approved for human use, and none of these peptides is a proven treatment for any medical condition.

Most stacking discussion comes from the research community rather than from regulated clinical guidance. The details below describe what is studied and reported, not a recommendation to use anything.

What CJC-1295 Does and Why People Stack It

CJC-1295 is a modified GHRH analog. It binds GHRH receptors in the pituitary gland and stimulates the release of growth hormone. The DAC version (Drug Affinity Complex) binds to albumin and stays active much longer, while cjc-1295 without drug affinity complex — often called CJC-1295 no DAC or mod GRF 1-29 — clears from the body quickly.

Stacking pairs CJC-1295 with an agent that works through a different receptor, most often a ghrelin receptor agonist such as ipamorelin. The theory is that two pathways produce a broader GH pulse than either compound alone. That theory is reasonable mechanistically, but it has not been confirmed in large human trials.

Common CJC-1295 Stacks Compared

Stack	Second peptide	Primary pathway	Research notes
CJC-1295 + ipamorelin	Ipamorelin (ghrelin agonist)	GHRH + ghrelin receptor	The most discussed pairing; early animal work described GH release with limited effects on cortisol or prolactin.
CJC-1295 + tesamorelin	Tesamorelin (GHRH analog)	GHRH only	Two GHRH analogs hitting the same receptor; no published trial of the combination.
CJC-1295 + sermorelin	Sermorelin (GHRH 1-29)	GHRH only	Short-acting; studied historically for pediatric GH deficiency as a single agent.
CJC-1295 + AOD-9604	AOD-9604 (hGH fragment 176-191)	Lipolytic fragment, not GHRH	Different target entirely; discussed for fat metabolism rather than GH release.

CJC-1295 and Ipamorelin

The CJC-1295 and ipamorelin combination is the most frequently discussed pairing, and the phrase cjc 1295 ipamorelin tesamorelin stack reflects how often people expand it to three peptides. Ipamorelin is a selective ghrelin receptor agonist that early animal studies described as producing GH release without large spikes in cortisol or prolactin.

Human data on the combination is thin. Small published trials exist for each peptide separately, but there is no large randomized trial of the pair used together.

Tesamorelin With CJC-1295

Because both compounds are GHRH analogs, a tesamorelin and cjc-1295 stack targets the same receptor twice. That raises a fair question about whether the combination adds anything beyond a single GHRH signal, and no published trial answers it. Tesamorelin is also the only peptide in this group with FDA approval, and only for HIV-associated lipodystrophy.

AOD-9604 Alongside a GH Stack

AOD-9604 is a fragment of human growth hormone that does not act on the GHRH receptor at all. When people compare aod-9604 vs cjc-1295 ipamorelin, they are usually weighing a fat-metabolism research peptide against a GH-release stack — different mechanisms rather than competing versions of the same thing.

How the Growth Hormone Axis Responds

CJC-1295 stimulates GHRH receptors. Ghrelin agonists like ipamorelin stimulate the ghrelin receptor, also known as GHS-R1a. Both signals converge on pituitary somatotroph cells, which release growth hormone in pulses rather than a steady stream.

Because GH release is pulsatile, the duration of each peptide matters. Long-acting CJC-1295 with DAC keeps receptor stimulation fairly steady, while short-acting peptides produce a sharper, shorter signal. Some researchers pair a long-acting GHRH analog with a short-acting ghrelin agonist to better mimic a natural pulse.

Reported Research Dosages

Dosing information in this space comes from studies of single peptides, not from trials of combinations. A frequently cited cjc-1295 ipamorelin dosage in research summaries is 100 mcg of each peptide per injection, one to three times daily, using the no-DAC version of CJC-1295. Long-acting CJC-1295 with DAC has been studied at roughly 30 to 60 mcg per kilogram of body weight once weekly or every other week.

These numbers are research references only. Self-dosing with unapproved peptides carries real risks, including injection-site reactions, fluid retention, joint discomfort, and changes in blood sugar regulation.

Safety, Legal Status, and Practical Caveats

• CJC-1295 is not FDA-approved for human use in the United States and is sold for laboratory research only.
• Tesamorelin is FDA-approved, but only for HIV-associated lipodystrophy — not for general weight loss or anti-aging use.
• Ipamorelin and AOD-9604 are not FDA-approved for human use.
• Online products are frequently mislabeled, underdosed, or contaminated, and independent testing is uncommon.
• Peptides that raise growth hormone can affect insulin sensitivity, fluid balance, and hormone-sensitive conditions.

Anyone with a medical concern about growth hormone, body composition, or recovery should speak with a licensed healthcare professional instead of self-experimenting. Prescription options such as tesamorelin are supervised for a reason, and a clinician can check for conditions that make GH-related compounds risky.

The Bottom Line

A CJC-1295 stack pairs a GHRH analog with a second peptide — usually ipamorelin — to act on more than one growth hormone pathway.

The strongest human evidence exists for single peptides, especially tesamorelin in its narrow approved indication. Combination stacks rest mostly on animal data, mechanistic reasoning, and anecdote.

Anyone researching these compounds should treat published dosing charts as references rather than instructions, verify sourcing claims skeptically, and weigh legal status before anything else.

COMMON QUESTIONS

Frequently Asked Questions

What is a CJC-1295 stack used for?

In research settings, a CJC-1295 stack is used to study whether combining a GHRH analog with a second peptide produces a broader growth hormone and IGF-1 response than either peptide alone. The most common pairing is CJC-1295 with ipamorelin. No stack is FDA-approved for human use, and none is an established treatment for any condition.

What is the typical CJC-1295 and ipamorelin dosage?

Research summaries often cite 100 mcg of CJC-1295 and 100 mcg of ipamorelin per injection, one to three times daily, using the no-DAC form of CJC-1295. Long-acting CJC-1295 with DAC has been studied at about 30 to 60 mcg per kilogram once weekly or every other week. These figures come from single-peptide studies and are not medical dosing recommendations.

Is CJC-1295 legal or FDA-approved in the United States?

CJC-1295 is not FDA-approved for human use in the United States and is legally sold only for laboratory research. Ipamorelin and AOD-9604 are also unapproved for human use, while tesamorelin is approved only for HIV-associated lipodystrophy. Buying or using unapproved peptides for personal use falls outside FDA oversight, so product quality and purity are not guaranteed.